Quick Answer
Valion Bio, Inc. reported Cash and Equivalents of $12.64 million for fiscal year 2025.
Valion Bio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $12.64M | +531.6% |
| 2024 | $2.00M | -41.0% |
| 2023 | $3.40M | -3.5% |
| 2022 | $3.52M | -72.9% |
| 2021 | $12.97M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.45M | +57.6% | +191.4% |
| June 30, 2025 | $1.18M | -67.9% | +77.0% |
| March 31, 2025 | $669.0K | -59.9% | -66.6% |
| December 31, 2024 | $2.00M | -41.0% | -8.5% |
| September 30, 2024 | $2.19M | -57.7% | -40.7% |
| June 30, 2024 | $3.69M | +38.9% | +121.4% |
| March 31, 2024 | $1.67M | -67.7% | -50.9% |
| December 31, 2023 | $3.40M | -3.5% | -34.3% |
- Valion Bio, Inc. showed an increase of +531.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Valion Bio, Inc.’s cash and equivalents has declined by 2.5% (from $12.97 million to $12.64 million).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: